Clinical Trial Update: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab and HER2Bi-armed activated T cells for metastatic castration-resistant prostate cancer has completed enrollment with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• HER2Bi-armed activated T cells (HER2Bi-armed activated T cells)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-11-15